pipette
ENEnglish

A multi-center retrospective chart analysis identifying clinical, biochemical, and radiographic signatures of short-chain enoyl-CoA hydratase (ECHS1) deficiency

C. Kong, C. Alves, G.-F. Vogel, R. Xiao, I. Anselm, G. Berry, J. F. Cabello, V. Cornejo, A. Cortes Fernandez, G. Enns, M. Gomez, C. Haldeman-Englert, S. Hollander, A. M. Innes, E. Jannotta, A. Kochhar, J. Kopesky, A. Larson, C. Lee, M. Lezcano, R. Li, M. Lines, J. Morrison, M. Muriello, E. Null, L. Pena-Quintana, E. Phelps, M. Saifeddine, M. C. Sanabria, R. P. Saneto, E. Shelkowitz, C. Tise, J. L. K. Van Hove, I. Elsharkawi, R. D. Ganetzky

PreprintUso en el mundo real

En palabras de los autores

Short-chain enoyl-CoA hydratase (ECHS1) catalyzes the hydration of C4-C6 acyl-CoA molecules to produce ATP in fatty acid {beta}-oxidation. Deficiency of the ECHS1 enzyme, ECHS1D, is a rare autosomal recessive disorder that presents with a large and pleomorphic clinical spectrum. We present the largest comprehensive study of known diagnosed ECHS1D patients to date, reporting 26 new patients and 8 novel variants in conjunction with a literature review of 87 previously reported patients. All patients were categorized into neonatal, infantile, and late-onset groups based on age of onset and clinical course. Neonatal-onset cases were characterized by early and severe multisystem disease, often with lactic acidosis, hypotonia, cardiomyopathy, and high early mortality (62.5%). The infantile-onset group was heterogeneous, but many exhibited hallmark features such as dystonia, developmental delay, and basal ganglia involvement on neuroimaging. Mortality was significantly lower than the neonatal cohort (24.4%). Late-onset patients had more localized neurologic symptoms, particularly dystonia, and significantly lower mortality overall (0%). Moreover, we report a 37.5% survival rate in newly reported neonatal onset patients compared with 18.2% in prior reports, possibly reflective of earlier recognition of ECHS1D and greater utilization of therapies including N-acetylcysteine, sodium dichloroacetate, and valine-restricted diet.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 6 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.05.26366953